Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics.
Journal: The Journal of antimicrobial chemotherapy
Published: November 14, 2024
Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials.
Journal: Critical care (London, England)
Published: July 24, 2024
Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomized trials of rezafungin versus caspofungin.
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: July 05, 2024
Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials.
Journal: Critical care (London, England)
Published: May 30, 2024
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.
Journal: Antimicrobial agents and chemotherapy
Published: March 25, 2024
Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: February 15, 2024
Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects.
Journal: Pharmacotherapy
Published: January 31, 2024
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Journal: The Lancet. Infectious diseases
Published: July 11, 2023
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations.
Journal: Microbiology spectrum
Published: May 08, 2023
Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: December 30, 2022
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
Journal: Lancet (London, England)
Published: October 13, 2022
A phase I randomized, double-blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects.
Journal: Clinical and translational science
Published: November 08, 2021
Last Updated: 09/26/2026